Phase 2Active, not recruitingAge-related condition
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy
- Sponsor
- Ono Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 92 enrolled
- Conditions
- Multiple System Atrophy (MSA)
- Interventions
- ONO-2808; Placebo
- Ages
- adults, older adults
- Registry
- NCT05923866
Full record on ClinicalTrials.gov
From the registry
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Primary outcomes
- Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
- Incidence of TEAEs by Highest Severity
- Incidence of Study Treatment-related TEAEs by Highest Severity
History
Study completion expected
Results first posted
Last registry update
Primary completion
Started
Registered